AmbrogioLab

Official account of Chiara Ambrogio´s Laboratory,

[Anna Obenauf @obenaufa]

Pls RT: Are you studying the multifaceted MAPK pathway? We would love to hear about your exciting research!
Abstract Deadline 👉16.12.2024 for the #virtualmeeting on "Drugging and regulating the #MAPKpathway"
organised with @EACRnews with @Boehringer https://t.co/hiyRqSB4En

[CrozrX @CrozrX]

📖 🎯
A new book!
RAS Drug Discovery
•
Past, Present and Future
🔸️
A comprehensive overview of the state-of-the-art medicinal chemistry approaches towards targeting the formerly undruggable oncogene, KRAS.
@Aiims1742 @AndresFCardonaZ @FredNatLab @Tony_Calles @chulkimMD @CentralParkWMD
@StephenVLiu @BenjaminBesseMD @EricTopol @gerlach_d @ArndtVogel @RonDePinho @DrYukselUrun @DavidHongMD @CadranelJ @pashtoonkasi @ChadPecot @JacobAdashek @AmbrogioLab 🔸️
https://t.co/eAeDAzLwt8

[Margaret Foti, PhD, MD (hc) @AACR_CEO]

I am excited for the next three days of @theNCI's RAS Initiative Symposium 2024. Today, @NCIDirector Rathmell and AACR Past President Frank McCormick kicked off this important meeting aimed at mobilizing the cancer research community to target RAS-driven cancers.

[Anna Obenauf @obenaufa]

Excited to co-organize the virtual @EACRnews @Boehringer Conference: Drugging & Regulating the MAP Kinase Pathway! Submit an abstract or join us. Please RT and share with others.

Details & registration:
https://t.co/KmKFU3xpcz

[AmbrogioLab @AmbrogioLab]

Our latest publication online now! https://t.co/uEMyfMV8jR @NatureComms
Amazing team work @lab_santamaria @MJNokin @BiagioRicciutMD @DrMarkAwad @NadalErnest @cereda_lab

[Marie-Julie Nokin @MJNokin]

Happy to share our new publication on redox sensitivities of drug persistent and resistant BRAF mutated lung cancer. @GIGA_ULiege @iecb_bordeaux @ciccancer @lab_santamaria @AmbrogioLab @frsFNRS @televie @FondationLeon https://t.co/YRshbiCvGH

[AmbrogioLab @AmbrogioLab]

Our PREDICT project is among the 2024 ERC Proof of Concept grants! @ERC_Research #ERCPoC

[European Research Council (ERC) @ERC_Research]

📣 Out now! First results of the 2024 ERC Proof of Concept call.

100 grants – each worth €150,000 – will help ERC grantees to bridge the gap between the discoveries stemming from their frontier research and their practical application.

More 👉 https://t.co/wcBn2eYMY0

[EACR @EACRnews]

EACR-@Mark Foundation Postdoctoral Fellowships are awarded for a period of three years and support excellent postdoctoral researchers in laboratories throughout Europe. Is that you? 👀

Apply by 21 August: https://t.co/o0qlBiCxhn

[Nuria Lopez-Bigas @nlbigas]

Mariano Barbacid receive the Mike Price Award ⁦@EACRnews⁩ #EACR2024 👏🏻👏🏻

[EACR @EACRnews]

There are just a few more days left to register for our upcoming Early-Career Researchers' Conference, happening online 25-26 June!

👉 Don't miss the 12 June deadline: https://t.co/fnQSypBNxy

[Lù Casini @LuCasini_PhD]

Stunning results from @CanaudLab who just presented their case study that led to an FDA-approved drug. Thanks @unito for organizing it! #research #24May

[EACR @EACRnews]

There's not long left to wait until the EACR Congress comes to the Netherlands in June! ☀️

Don't miss the opportunity to take advantage of our discounted early registration rate to attend, available until 29 April.

https://t.co/dYUl2wD7aL

[Cancer Discovery @CD_AACR]

Read the #CancerHallmarks Perspective—
Piecing the Puzzle Together.
https://t.co/ZrOB7zHVp8
@AmbrogioLab @MariaPAlcolea @gemmakelly_1 @waileongtam @theLundLab @alpcorreia @CJHPhD @IngunnStromnes @DanielaQuail @ErnstAurelie @DirenaAC @ShemaEfrat @BullmanLab @Marcus_Ruscetti

[AmbrogioLab @AmbrogioLab]

@iannaconelab Congrats Matteo!!

[Dr Ino Agrafioti @inoagrafioti]

Can you believe we got to fund 9 LS1 @ERC_research grants?!?🤩HUGE congratulations to:@clausen_lab, @Archaellum,T. Hoppe @CECAD_ , @Tampe_Lab, Y. Senis @Inserm, M. Glickman @BiologyTechnion, M. Foiani @IFOMresearch, @photosyn_Adam & @hecklab! Amazing&very diverse set of projects!

[Cancer Discovery @CD_AACR]

Just published with the #AACR24 presentation in Attacking #KRAS Beyond G12C:
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers, by Jingjing Jiang, Zhengping Wang, Mallika Singh et al.
https://t.co/CkAxQMGNRh
#RevolutionMedicines

[Carmen Mecca @CarmenMeccaPhD]

@BiagioRicciutMD from @DanaFarber is presenting today at #AACR2024 section 41 poster 18 new data on wild type KRAS amplification as a de novo oncogenic driver in NSCLC. Terrific work done in collaboration with @AmbrogioLab. @DrMarkAwad @KRASKickers

[Daniel Gerlach @gerlach_d]

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy | Nature #AACR24 https://t.co/PXsypsqCCD

[Anirban Maitra @Aiims1742]

Out in @Nature concurrent with #AACR24
Two papers on biochemistry and preclinical characterization of Revolution Medicines’ RAS(ON) multiRAS inhibitor, with a focus on #PancreaticCancer
@KenOliveLab @BenStanger01 @derlabunc
https://t.co/Ptzrxtj39x
https://t.co/k5Q2buC8h0

[AmbrogioLab @AmbrogioLab]

@DirenaAC @CD_AACR @IRBBarcelona @MSKCancerCenter @LoweLabMSKCC @msmelanoma Congrats Direna!! 👏🏻👏🏻👏🏻